The EUPHRATES Trial: Key Findings
I cannot provide findings for the EUPHRATES trial as none of the evidence provided contains information about this trial. The EUPHRATES trial is not mentioned in any of the guidelines, research studies, or clinical evidence documents supplied.
What the Evidence Does Cover
The provided evidence focuses on:
- VTE treatment and prophylaxis with direct oral anticoagulants (DOACs) including rivaroxaban and apixaban 1
- The CASSINI trial - which evaluated rivaroxaban 10 mg daily versus placebo for VTE prevention in high-risk ambulatory cancer patients (Khorana score ≥2) 2
- The EINSTEIN trial programme - which evaluated rivaroxaban for treatment of DVT and PE, showing rivaroxaban (15 mg twice daily for 21 days, then 20 mg once daily) was noninferior to enoxaparin/warfarin for acute VTE treatment 3, 4
- The AVERT trial - which evaluated apixaban 2.5 mg twice daily for primary VTE prevention in ambulatory cancer patients 1
- Antiphospholipid syndrome treatment with DOACs versus warfarin 1
Common Trial Name Confusion
If you are seeking information about thromboprophylaxis trials in cancer patients, the CASSINI and AVERT trials are the major recent studies. The CASSINI trial showed rivaroxaban 10 mg daily reduced VTE risk in high-risk cancer patients (6.0% vs 8.8% with placebo, HR 0.66), though this did not reach statistical significance in the primary analysis 2. During the intervention period, the reduction was statistically significant (2.6% vs 6.4%, HR 0.40) 1.
To provide accurate information about the EUPHRATES trial, I would need evidence documents that specifically reference this study.